Background
Peripheral artery disease (PAD) is an atherosclerotic vascular disease that affects the blood vessels other than those in the coronary circulation. The cause of symptomatic PAD is atherosclerosis, vascular dysfunctions, impaired angiogenesis and neointima formation and the prevalence is increased with age and is a growing health problem worldwide. It has been estimated that approximately 10% of men between 65 and 74 years have PAD [
1], which is associated with an increased mortality rate of 25–30% [
2‐
5]. Studies of the future need for vascular surgery in PAD patients predicts that vascular procedures will increase from 1.39 million in 2015 to 1.6 million in the adult population by 2020 in US [
6].
Symptomatic PAD can present as intermittent claudication (IC) or as critical lower-extremity ischemia (CLI). CLI is a life-treating syndrome and associated with high risk of amputation [
7‐
10]. The proportion of diagnosed CLI patients is approximately 40% of hospitalized PAD patients [
11]. The clinical manifestations of the disease are seen after the establishment of the flow-limiting atherosclerotic plaque and symptoms include intermittent claudication leg pain, rest pain, and ischemic ulcers. PAD patients further present with increased cardiovascular mortality [
12] and increased functional decline compared to non-PAD [
13]. The current treatment includes lifestyle changes, surgical revascularization [
14] and medical therapy targeted at lowering atherosclerotic vascular diseases, which results in significant lowering of morbidity and mortality associated with PAD [
15]. Consequently, targeted screening of at-risk patients using measurements of ankle–brachial index (ABI) is recommended [
16]. Moreover, serum biomarkers have been used experimentally for the prediction and detection of PAD [
17,
18], but although clear associations have been demonstrated, the overall clinical value related to patient outcomes remains unclear.
As such, identification of new biomarkers of symptomatic PAD is vital for early discovery and treatment of patients. Indication of biological processes, for instance, resulting in increased risk of needing vascular reconstruction or developing CLI has the potential to reduce the worsening of symptoms and thus the morbidity and mortality of symptomatic PAD patients. In the present study, we envisioned that microfibrillar-associated protein 4 (MFAP4) could serve as such a marker.
MFAP4 is an oligomeric extracellular matrix (ECM) protein belonging to the fibrinogen-related domain (FReD) super family, which also includes members such as angiopoietin and tenascin [
19]. Besides the C-terminal FReD, the MFAP4 sequence harbors a N-terminal RGD sequence with integrin binding and activating capacity [
20‐
22]. MFAP4 directly binds to collagen, elastin and fibrillin [
23] and it is localized to ECM fibers in the heart and arteries throughout the body [
24].
Mfap4-deficient mice have been generated but did not reveal any distinct role of MFAP4 in normal physiology, although the adult mice developed a mild airspace enlargement compatible with subtle elastic defects [
25]. In contrast, in vivo studies have demonstrated direct roles for MFAP4 in vascular occlusive remodeling with delayed neointimal formation and blunted outward remodeling after carotid ligation in
Mfap4-deficient mice [
22]. MFAP4 is further found in a soluble form and serum MFAP4 (sMFAP4) levels are recognized to vary with cardiovascular disease [
24] and pulmonary disease [
26] although the strongest association is found with high sMFAP4 and liver cirrhosis [
27‐
29]. In the present study, we hypothesized that sMFAP4 is positively associated with the symptomatic PAD outcomes cardiovascular disease (CVD) death, 2-year primary patency after reconstructive surgery, and CLI.
Discussion
The purpose of this study was to investigate whether sMFAP4 was positively associated with the following symptomatic PAD outcomes; CLI diagnosis, CVD death, and 2-year primary patency after vascular reconstruction. We observed a significant direct correlation between the upper sMFAP4 tertile and CLI. In addition, we observed that upper tertile sMFAP4 was significantly associated with CVD death in analyses adjusting for age, sex, smoking and BMI. Surprisingly, patients with upper tertile sMFAP4 had a significantly decreased risk of occlusion of their reconstructed vessel. The latter relationship may be explained by that there is a rather limited overlap between those patients with vascular occlusion after surgery, and CVD death and/or CLI in the present cohort (Fig.
1). Thus, a large proportion of patients with vascular occlusion after reconstructive surgery had IC (18/27) and no CVD death or CLI and sMFAP4 may be regulated differently in IC versus CLI or processes leading to CVD death.
This is to our knowledge the first observation that associates sMFAP4 to CLI, CVD death, and vascular occlusion after reconstructive surgery and the observation supports the hypothesis that sMFAP4 may serve as a prognostic marker in symptomatic PAD. As such, sMFAP4 has the potential to identify patients that are in risk of developing CLI or CVD death. However, it is currently unknown if high sMFAP4 develops as a consequence of disease and if a series of consecutive measurements therefore might be more informative than the present baseline measurement. Moreover, the study was not originally designed to test if inclusion of sMFAP4 into risk assessment based on ABI and Framingham risk scores would add value to a screening program.
Previous studies of clinical sMFAP4 variation showed that the level of sMFAP4 can be correlated to the other cardiovascular risk markers; fibulin-1, osteoprotegerin and ostepontin [
24]. Basic studies performed by our group have shown that MFAP4 is involved in vascular smooth muscle hyperplasia, neointima formation and vascular remodeling in vivo [
22]. The former studies in
Mfap4-deficient mice have thus identified a mechanistic role of MFAP4 in vascular biology involved in vascular complications of PAD. Other observations have shown that both local MFAP4 expression and serum levels of MFAP4 are increased in liver fibrosis/cirrhosis [
28,
29,
32] and moreover are moderately regulated in COPD [
26]. On this basis, we do not suggest that MFAP4 is a disease-specific marker for symptomatic PAD.
A possible explanation of our present observations of the increased level of sMFAP4 in symptomatic PAD patients with the most severe outcomes may be that vascular bed remodeling and/or ischemia causes tissue disruption and release of ECM molecules, including MFAP4, into the circulation as seen previously [
33]. The surprising association between the lowest sMFAP4 and increased risk of vascular occlusion after reconstructive surgery could indicate that certain events occurring in the vessels may contribute to destruction of MFAP4 as it is seen for matricellular proteins such as osteopontin [
34,
35]. However, it was not examined if or to what degree sMFAP4 was degraded in the present study.
Limitation of the present study is furthermore that we do not have matched controls, that uncontrolled confounding and information bias might be present and that there was limited follow-up on CVD death in this study. Thus larger cohorts are warranted to confirm our observations. The strength of this study is that the prospective design has been used previously in several studies [
30,
36‐
38]. Moreover, a relatively long duration of follow-up is present in this study.
Authors’ contributions
Conceived and designed the statistical analyzes: LEH, JSL, GLS. Performed the measurements and the statistical analyses: LEH, JSL, GLS. Contributed with materials and analysis tools: JSL, AS. Wrote the paper: LEH, JSL, GLS. All authors read and approved the final manuscript.